REG - Faron Pharma. Oy - Faron commences a share offering

Faron Pharmaceuticals OyAnnouncement

04/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240604:nRSD0099Ra&default-theme=true

RNS Number : 0099R  Faron Pharmaceuticals Oy  04 June 2024

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Inside Information: Faron commences a share offering of preliminarily a
maximum of 30,714,592 Offer Shares at a subscription price of EUR 1.00 per
Offer Share and publishes a prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC
OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE
WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR
CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY
PERSON TO ACQUIRE ANY SECURITIES. PLEASE SEE THE IMPORTANT NOTICES AT THE END
OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 ("MAR") AND ARTICLE 7 OF MAR AS IT FORMS PART OF
DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN
MAR AND UK MAR) WERE TAKEN IN RESPECT OF THE TRANSACTION WITH THE RESULT THAT
CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN MAR AND UK
MAR), AS PERMITTED BY MAR AND UK MAR. THIS INSIDE INFORMATION IS SET OUT IN
THIS ANNOUNCEMENT. THEREFORE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION
IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION
RELATING TO THE COMPANY AND ITS SECURITIES.

 

Company announcement, 4 June 2024 at 9:00 (EEST) / 7:00 (BST) / 2:00 AM (EDT)

Inside information

 

Key highlights

 

·    Faron announces an offering of approximately EUR 30.7 million in
total by offering for subscription preliminarily a maximum of 30,714,592 new
and/or treasury shares (the "Offer Shares") at a subscription price of EUR
1.00 per Offer Share (the "Subscription Price") (the "Offering").

·    The Offering will be conducted as a directed share issue by way of
(i) a public offering to private individuals and legal entities in Finland
(the "Public Offering") and (ii) an institutional offering to institutional
investors in the European Economic Area and, in accordance with applicable
laws, internationally (the "Institutional Offering"). Moreover, there will be
 (a) a separate open offer to qualifying holders of depositary interests in
the United Kingdom and elsewhere (the "UK Open Offer"); and (ii) a separate
retail offer to retail investors in the United Kingdom on the "REX" platform
(the "REX Retail Offer"), through which a part of the amount of proceeds
sought by the Company in the Offering may be raised.

·    The objective of the Offering is to strengthen the Company's cash
position so that the Company would have sufficient funding to reach its key
milestones for the year 2024, i.e. a significant commercial partnership
agreement and to finance the Company's product development costs until the
latter half of March 2025, that mainly include the production and research
costs in respect of the Company's lead program bexmarilimab. If the Company
succeeds in completing the Offering of approximately EUR 30.7 million, the
Company believes it would have sufficient resources to execute its core
business and deliver on its key milestones of the year 2024 under the current
business plan and in compliance with the financial covenants of the facilities
agreement entered into with IPF FUND II SCA, SICAV-FIAR ("IPF") (the "IPF
Facilities Agreement") until the latter half of March 2025.

·    The Offering is conditional upon the Company raising at least EUR 15
million in gross proceeds. The Company has obtained:

o  binding subscription commitments in the aggregate amount of approximately
EUR 6.2 million (the "Subscription Commitments"); and

o  binding subscription guarantee undertakings whereby the subscription
guarantors have undertaken to subscribe for any new shares of the Company not
subscribed for in the Offering in an aggregate amount of up to EUR 8.8
million, as described below (the "Subscription Guarantee Undertakings"). The
Subscription Guarantee Undertakings are limited to cover any unsubscribed new
shares in the Company up to the minimum gross proceeds of the Offering of EUR
15 million.

·    Based on the binding Subscription Commitments and Subscription
Guarantee Undertakings received by the Company, the condition of raising at
least EUR 15 million in gross proceeds has been fulfilled.

·    The subscription period for the Offer Shares will commence on 5 June
2024 at 10:00 a.m. Finnish time and end on 18 June 2024 at 4:00 p.m. Finnish
time for the Public Offering and on 19 June 2024 at 9:30 a.m. Finnish time for
the Institutional Offering (the "Subscription Period").

·    The Subscription Price in the Offering has been determined on market
terms, based on feedback received from the market in advance and investors'
price indications, and it includes a significant discount to the market price
of the Company's shares prior to the announcement of the Offering. No
subscription rights will be issued in the Offering, and therefore cannot be
subject to public trading. The Offering dilutes current shareholders'
ownership share in the Company, unless the current shareholders subscribe for
the Offer Shares in the Offering.

·    The Offering can be completed even if it is not subscribed in full,
in which case the Company's funding would not be sufficient to deliver on the
Company's key milestones of the year 2024 in accordance with the current
business plan and it would have to adjust and reduce its operations and
negotiate changes to its terms of payment or negotiate new amendments to its
financial covenants and seek additional funding earlier than currently
planned.

·    Carnegie Investment Bank AB, Finland Branch ("Carnegie") and Peel
Hunt LLP ("Peel Hunt") are acting as lead managers (the "Lead Managers") and
bookrunners for the Offering. Carnegie is not participating in arranging the
UK Open Offer or the REX Retail Offer and Peel Hunt is not participating in
arranging the UK Open Offer.

·    The Company has prepared a Finnish language prospectus, which will be
available on the Company's website at www.faron.com/osakeanti and on Nordnet
Bank AB's website at www.nordnet.fi/faron no later than 4 June 2024. An
unofficial English language translation of the prospectus will be available on
the Company's website at www.faron.com/publicoffer no later than 4 June 2024.

 

TURKU, FINLAND - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company pursuing a CLEVER-1 receptor
targeting approach to reprogramming myeloid cells to activate anti-tumor
immunity in hematological and solid tumor microenvironments, today announces
that it will commence a share offering. The aim of the Company is to
strengthen its cash position so that the Company would have sufficient funding
to reach its key milestones for the year 2024, i.e. to reach a significant
commercial partnership agreement and to finance its product development costs
until the latter half of March 2025, that mainly include the production and
research costs in respect of the Company's lead program bexmarilimab.

 

Based on the authorisations granted at the annual general meetings of the
Company on 5 April 2024 and 24 March 2023, the Board of Directors of the
Company has resolved on 3 June 2024 on terms for the Offering of approximately
EUR 30.7 million in total by offering for subscription preliminarily up to
30,714,592 Offer Shares. The Board of Directors of the Company may, in the
event of an oversubscription, increase the number of Offer Shares offered in
the Offering by a maximum of 8,000,000 Offer Shares (the "Upsize Option"). If
the Upsize Option is used in full, the number of Offer Shares offered shall
amount up to 38,714,592 shares of the Company in aggregate.

 

 

The Offering in brief:

 

·    The Company is offering for subscription preliminarily up to
30,714,592 Offer Shares in the Offering comprising the Public Offering and the
Institutional Offering.

·    The Subscription Price, EUR 1.00 per Offer Share, has been determined
on market terms, based on feedback received from the market in advance and
investors' price indications, and it includes a significant discount to the
market price prior to the announcement of the Offering. The Company's Board of
Directors has confirmed the Subscription Price based on negotiations between
the Company, the Lead Managers, and several potential investors regarding the
investors' prerequisites to participate in the Offering in a manner enabling
its completion, and the pricing of the Offering, taking into account the
Company's financial situation and the uncertainty regarding the continuation
of the Company's operations.

·    The Subscription Price corresponds to a discount of approximately 58
per cent compared to the closing price of the Company's current share EUR
2.36, a discount of approximately 61 per cent compared to EUR 2.57, i.e. the
30 days volume-weighted average trading price of the Company's share, and a
discount of approximately 49 per cent compared to EUR 1.98, i.e. the 90 days
volume-weighted average trading price of the Company's share on the First
North marketplace on the trading day immediately preceding the decision on the
Offering 31 May 2024.

·    In the Public Offering, the Subscription Price shall be paid in
euros. In the Institutional Offering, the Subscription Price shall be paid in
euros and/or by way of setting off the principal, any accrued interest and any
unpaid arrangement fees relating to convertible capital loan instruments
issued by the Company to certain investors in March 2024 (the "Capital
Loans").

·    Based on the binding Subscription Commitments and Subscription
Guarantee Undertakings received by the Company, the condition of gross
proceeds of at least EUR 15 million has been fulfilled.

·    In the Public Offering, the minimum subscription is 750 Offer Shares
and the maximum subscription is 99,999 Offer Shares. The minimum subscription
in the Institutional Offering is 100,000 Offer Shares. Multiple subscriptions
by the same investor shall be combined into one single subscription, subject
to the aforementioned maximum and minimum subscription amounts.

·    In the Public Offering, Offer Shares are offered for subscription to
individuals and legal entities in Finland. Investors whose permanent address
or domicile is in Finland and who subscribe Offer Shares in Finland may
participate in the Public Offering.

 

·    The Company aims to raise through the Offering a total of
approximately EUR 30.7 million, of which amount, approximately EUR 3.7 million
will be paid by converting the Company's Capital Loans and related arrangement
fees and interests into shares in the Company, gross proceeds of approximately
EUR 27 million, and net proceeds of approximately EUR 23 million.

·    If the Company succeeds in completing the Offering of approximately
EUR 30.7 million, the Company believes it would have sufficient resources to
execute its core business and deliver on its key milestones for the year 2024
under the current business plan and in compliance with the financial covenants
of IPF's Facilities Agreement until the latter half of March 2025.

·    The Company will likely complete the Offering even though its
targeted amount would not be reached. In such situation, the Company's funding
would not be sufficient to deliver on all of the Company's key milestones for
the year 2024 in accordance with the current business plan and the Company
would have to seek additional funding earlier than currently planned to fulfil
its current financing needs and financial covenants included in the IPF
Facilities Agreement. The financial scenarios have been described below in
more detail (see "Reasons for the Offering and use of proceeds; Scenarios for
the outcome of the Offering").

·    The structure of the Offering as a directed share issue rather than a
rights issue is due to the challenges involved due to the admission of the
Company's Shares to trading on AIM and the post-Brexit regulatory environment.
The structure and reasons for it have been described in the notice of the
Annual General Meeting 2024 when seeking the share issue authorisation for the
Board.  No subscription rights will be issued in the Offering, and therefore
cannot be subject to public trading due to which the current shareholders of
the Company cannot receive compensation typical of a rights issue for the sale
of subscription rights in the Offering.

·    For the Company to be able to strengthen its financial position,
secure the continuation of its operations and create preconditions for
delivering on its key milestones for the year 2024 described above in
accordance with its current business plan, the Board of Directors of the
Company considers that there is a weighty financial reason for the Company to
deviate from the shareholders' pre-emptive subscription right.

·    The Offer Shares issued in the Offering (without the Upsize Option)
amount to approximately 42.7 per cent of the shares and votes in the Company
prior to the Offering and approximately 29.9 per cent of the shares and votes
in the Company following the Offering. The number of outstanding shares in the
Company may be increased by a maximum of 41,371,666 shares (i.e. to a total
maximum of 113,379,163 shares) when the Upsize Option is exercised in full,
the Free Shares (as defined below) are issued as a result of the completion of
the Offering as well as assuming that all subscription guarantors would decide
to receive their subscription guarantee fee in Shares instead of euros. This
would result in approximately 36.5 per cent dilution of the total shareholding
of current shareholders.

·    The lenders of the Capital Loans have agreed, pursuant to the terms
of the Capital Loans, to convert principal, any accrued interest and any
unpaid arrangement fees relating to Capital Loans in the total aggregate
amount of EUR 3.7 million into Offer Shares in the Offering, corresponding to
approximately 3,714,592 Offer Shares and representing approximately 12 per
cent of the aggregate number of the Offer Shares (assuming that the Upsize
Option is not used).

·    The Company has committed to issue investors who participated in the
private placement announced on 4 April 2024 new shares primarily through a
free issue ("Free Shares"), so that the subscription price of the private
placement (EUR 1.50 per share) would be equal to the subscription price of a
public offer or other share issue that may have been completed with a lower
subscription price (or that it will make a corresponding compensation in
another way). As the Subscription Price in the Offering is EUR 1.0 per Offer
Share, the Company would issue 1,600,153 Free Shares in total.

·    The Board of Directors decides on the procedures to be followed in
case of under- or oversubscription and may also decide to not complete the
Offering (or the UK Offering). The Board of Directors of the Company may, in
the event of an oversubscription, increase the number of Offer Shares offered
in the Offering by a maximum of 8,000,000 Offer Shares. If the Upsize Option
is used in full, the number of Offer Shares offered shall amount up to
38,714,592 shares of the Company in aggregate. In case of oversubscription of
the Offering or when the aggregate number of subscriptions for the Offering
and the UK Offering exceed EUR 30.7 million, the Board of Directors of the
Company may reduce subscriptions. The Board of Directors has the right to
reduce large subscriptions relatively more than small subscriptions. In case
of oversubscription, the Board of Directors of the Company may prioritise the
allocation of Offer Shares to: (i) first to lenders of the Capital Loans; (ii)
secondly to subscribing shareholders of the Company who are registered in the
shareholder register of the Company maintained by Euroclear Finland Oy as at 6
June 2024, to whom, based on their ownership as at the date mentioned, a pro
rata allocation is intended to be provided, and thereafter to (iii) investors
who have committed to subscribe. In any event, valid applications by
qualifying holders of DIs will be satisfied in full up to their basic open
offer entitlements under the UK Open Offer.

·    The Company's Board of Directors will decide, on or about 19 June
2024 (unless the Subscription Period is extended) on the completion of the
Offering, on the final number of Offer Shares to be issued (including on the
exercise of the Upsize Option) and on the acceptance of subscriptions made in
the Offering in full or in part. The Company's Board of Directors decides on
the allocation of the Offer Shares between the Public Offering and the
Institutional Offering

·    An application will be made for the admission to trading of the Offer
Shares on the First North under the current trading code "FARON", and under
the trading code "FARN" on AIM. Trading in the Offer Shares is expected to
commence on or about 24 June 2024, unless the Subscription Period (as defined
below) is extended and subject to the admission of the Offer Shares to trading
on First North and AIM.

 

 

Open Offer and REX Retail Offer in brief

 

·    In the separate share offering in the United Kingdom, the Company may
raise up to approximately GBP 6.8 million (equated to EUR 8.0 million based on
an exchange rate of 1.1714 on 31 May 2024) through (i) an open offer of up to
approximately 5.8 million new shares of the Company (the "UK Open Offer
Shares") to qualifying holders of depositary interests ("DIs") representing
entitlements to shares in the Company in the United Kingdom and elsewhere on
the relevant record date ("Qualifying DI Holders") at a UK subscription price
of GBP 0.85 per share (the "UK Open Offer") and (ii) an offer of new shares of
the Company to retail investors in the United Kingdom through intermediaries
using Peel Hunt LLP's Retail Capital Markets Platform at a UK subscription
price of GBP 0.85 per share (the "REX Retail Offer" and together with the UK
Open Offer, the "UK Offering"). The total consideration under the UK Offering
cannot exceed the GBP equivalent of EUR 8 million, and excess allocations
under the UK Open Offer and allocations under the REX Retail Offer shall be
scaled back accordingly to ensure this. The subscription price for shares in
the UK Offering is equivalent to the EUR 1.00 Subscription Price of the
Offering based on an exchange rate of 1.1714 on 31 May 2024. The UK Open Offer
is governed by separate terms and conditions to be included in a circular
published by the Company (the "UK Open Offer Circular") and does not form part
of the Offering. The REX Retail Offer is governed by separate terms and
conditions to be included in the announcement of the REX Retail Offer and does
not form part of the Offering. Further details of the UK Open Offer are set
out below under "Details of the UK Open Offer". Further details of the REX
Retail Offer will be set out in a separate announcement.

·    The issue price of GBP 0.85 per share (the "UK Issue Price") in the
UK Offering corresponds to a discount of approximately 54 per cent compared to
the closing price of the Company's ordinary shares of GBP 1.85, and a discount
of approximately 61 per cent compared to GBP 2.18, i.e. the 30 days
volume-weighted average trading price of the Company's ordinary shares, and a
discount of approximately 52 per cent compared to GBP 1.78, i.e. the 90 days
volume-weighted average trading price of the Company's Share on AIM on the
trading day immediately preceding the resolution on the Offering 31 May 2024.

 

 

Dr. Juho Jalkanen, CEO of Faron, comments:

 

"Years of hard work and dedication are finally expected to come to life over
the next nine months as we seek to complete Phase II of our BEXMAB trial in
patients with relapsed or refractory higher-risk myelodysplastic syndrome (r/r
MDS), obtain regulatory feedback regarding measures required to obtain
regulatory approval in the U.S. and complete a partnership agreement for the
last stages of development and commercialization of bexmarilimab. With the
unmet need in r/r MDS, current competitive landscape, untapped market
opportunity and exceptional Phase I and initial Phase II read-outs we feel we
could possibly offer a unique opportunity for value inflection. Join us in
transforming the care of r/r MDS patients that have very limited treatment
options and extremely poor prognosis.

 

Many of you may not know, that r/r MDS is as lethal as pancreatic cancer. We
can possibly change this, which would be truly remarkable. For me it also
gives great pleasure that we can offer this investment opportunity to the
general public with the same terms and discounts as we do to institutional
investors. Now everyone can take part and share the excitement of the upcoming
year."

 

Tuomo Pätsi, Chairman of the Board of Faron, comments:

 

"Faron is currently at a very interesting stage. The preliminary results from
the Phase II study of our bexmarilimab drug candidate have been excellent and
confirmed the previous positive Phase I results. Now, our goal is to bring
bexmarilimab to market as quickly as possible, as patients are waiting for
such new treatment options. The planned share issue is therefore crucial so
that we would have sufficient funding to finance our product development and
to sign a significant commercial partnership agreement by the end of 2024."

 

Background to the Offering and Deviation from the Shareholders' Pre-emptive
subscription right

 

The Company announced on 4 March 2024 that it expects to require EUR 35
million in financing to complete the enrolment of patients for the BEXMAB
Phase II trial with interim and final readouts and to obtain regulatory
feedback from the FDA regarding path to regulatory approval in the U.S.
Earlier this year, the Company has raised financing totalling EUR 8 million
(including the EUR 3.2 million convertible Capital Loans announced on 4 March
2024, and paid to the Company on 8 March 2024, and the EUR 4.8 million
directed share issue, the completion of which was announced on 4 April 2024),
to secure continued compliance with the minimum cash covenant agreed in the
waiver with IPF. Thereafter, the Company has assessed preconditions for
arranging a larger financing round and now the Company aims, based on the
investigations of various alternatives, to conclude the Offering.

 

Due to the admission of the Company's shares to trading on AIM and the number
of DIs (representing shares in the Company) held by DI holders in the United
Kingdom, arranging a rights issue in a post-Brexit regulatory environment
would involve separate regulatory approval processes in Finland and the UK.
Arranging a rights issue in the UK would be challenging, time consuming and
expensive and not feasible in the Company's current financial situation. On 5
April 2024, the Company's Annual General Meeting granted an authorisation for
a directed share issue with broad discretion for the Board of Directors to
allow flexibility for the Company to arrange the contemplated offering in a
manner involving the Company's shareholders, in a timely manner and at the
most beneficial terms available. Hence, the now contemplated financing round
is structured as (i) a public offering of shares in Finland with private
placements in the EEA and elsewhere (i.e. the Public Offering and the
Institutional Offering), and (ii) a separate UK Offering, the aggregate amount
of which shall always be less than EUR 8 million. In the Offering, the current
shareholders of the Company do not receive subscription rights, but they have
the right to participate in the Offering and subscribe for the Offer Shares in
accordance with the terms and conditions of the Offering.

 

The Company has applied for and received a statement from the Market Practice
Board of the Finnish Securities Market Association (Decision Recommendation
1/2024) on the compliance of the Offering with good securities market
practice. In its decision recommendation, the Market Practice Board has
concluded that, in the circumstances described in the application, the planned
directed share issue described in the application is in accordance with good
securities market practice, provided that the subscription price in the share
issue is determined on market terms. The Market Practice Board has in its
recommendation also noted that the issuer shall, when disclosing information
on the directed share issue, thoroughly and clearly describe information on
the directed share issue, the reason for deviating from the shareholders'
pre-emptive subscription right and the determination of the subscription
price. When disclosing information on the share issue and marketing, the
issuer may not create a misleading understanding that the share issue would be
based on the shareholders' pre-emptive subscription right.

 

Reasons for the Offering and use of proceeds; Scenarios for the outcome of the
Offering

 

The objective of the Offering is to strengthen the Company's cash position so
that the Company would have sufficient funding to reach its key milestones for
the year 2024, i.e. a significant commercial partnership agreement and to
finance its product development costs described below until the latter half of
March 2025. The product development costs mainly include the production and
research costs in respect of the Company's lead program bexmarilimab, i.e.
costs related to the completion of enrolment of the patients for the BEXMAB
Phase II trial, treatment of patients and publication of readouts as well as
obtaining regulatory feedback from the FDA regarding measures required to
obtain regulatory approval in the U.S. By the end of 2024, the Company is also
aiming to conclude a global partnership agreement to fund Phase III clinical
research and to commercialise bexmarilimab, and it believes that the better
the Company is financed the better its position is to conclude a partnership.
If the Company succeeds in completing the Offering of approximately EUR 30.7
million, the Company believes it would have sufficient resources to execute
its core business and deliver on its key milestones of the year 2024 under the
current business plan and in compliance with the financial covenants of the
IPF Facilities Agreement until the latter half of March 2025. The reasons for
the UK Offering are the same as described above.

 

The Company estimates to use approximately two-thirds of the net proceeds of
the Offering towards product development costs included in its key milestones
for the year 2024, i.e. the continuation of the BEXMAB Phase II trial,
including site and patient enrolment expenses and the drug's CMC (Chemistry,
Manufacturing, and Controls) related drug product costs, which result from its
preparations for Phase III. The Company will also incur costs from an
investigator-initiated study to generate data with anti-PD-1 combinations in
solid tumors. The balance of the net proceeds will be used for financing costs
and repayments of its existing financing agreements (IPF Facilities Agreement,
loan agreement with Business Finland and the Company's lease agreements),
general and administrative expenses, working capital and general corporate
purposes of the Company. The Company intends to use approximately EUR 3
million in total of the net proceeds towards repayments under the financing
agreements mentioned above during the period between June 2024 and February
2025.

 

The Company will likely complete the Offering even though its targeted amount
would not be reached. In such situation, the Company's funding would not be
sufficient to deliver on all of the Company's key milestones for the year 2024
in accordance with the current business plan and the Company would have to
seek additional funding earlier than currently planned to fulfil its current
financing needs and financial covenants included in the IPF Facilities
Agreement. The following is an estimate of the sufficiency of the gross
proceeds to be received from the Offering (including the UK Offering) in
different situations. The Offering is conditional upon the Company raising at
least EUR 15 million in gross proceeds and the Subscription Guarantee
Undertakings received by the Company are limited to this minimum amount of the
Offering:

 

·    With the EUR 15 million gross proceeds, the Company's funding could
be sufficient until it receives regulatory feedback from the FDA regarding
measures required to obtain regulatory approval in the U.S. The Company would
have some more time to obtain further clinical results from the current
patients as well as recruit some additional patients. The Company would target
and focus primarily on achieving a licensing or partnership agreement as soon
as possible. With the EUR 15 million gross proceeds (approximately EUR 12
million net proceeds) the Company expects that it is able to comply with its
current financial covenants until the end of September 2024. If the Company
conducts negotiations with the vendors of accounts payable and achieves a
favourable outcome, and agrees on changes to the payment schedules, the
Company would be able to comply with its current financial covenants until the
end of the year 2024.

 

·    If the gross proceeds received from the Offering would be at least
EUR 23 million, the Company would pursue the completion of Phase II of the
BEXMAB clinical trial and the Company estimates that it would be able to
comply with its current financial covenants until the beginning of January
2025. The Company would have the opportunity to devote more time and resources
to negotiating and concluding a licensing or partnership agreement before the
beginning of January 2025.

 

·    If the gross proceeds received from the Offering would be EUR 27
million, the Company would pursue readiness to proceed to Phase III clinical
trial, which would, in the Company's opinion, improve its negotiating position
in future partnership negotiations, and the Company estimates that it would be
able to comply with its current financial covenants until the latter half of
March 2025. The Company could have sufficient clinical results and time to
improve its negotiating position significantly in negotiating and concluding a
commercial partnership agreement.

 

If the Company succeeds in raising more funds through the Offering than the
aimed total amount of EUR 27 million in gross proceeds, the Company could
achieve the above-mentioned objectives and it would have a stronger balance
sheet to conduct commercial negotiations. The proceeds received with the
potential Upsize Option would be used to strengthen the Company's balance
sheet, as well as to preparation for the Phase III clinical trial.

 

Subscription Commitments and Subscription Guarantee Undertakings

 

Certain current shareholders of the Company and other investors have, each
separately, committed to subscribe for Offer Shares in the Offering for a
total of EUR 6.2 million and to pay the Subscription Price for such Offer
Shares (the "Subscription Commitments"). The Subscription Commitments cover
subscription of the Offer Shares for a total value of approximately EUR 6.2
million, which corresponds to approximately 6,238,724 Offer Shares, and
represent approximately 20 per cent of the total number of the Offer Shares
(assuming the Upsize Option is not used).

 

The Subscription Commitments are binding, irrevocable and subject only to the
fulfilment of the following conditions: (i) the subscription price per new
share of the Company in the Offering shall not exceed EUR 1.0, (ii) the Board
of Directors of the Company having no later than 30 June 2024 resolved to
commence the Offering and (iii) the Company raises gross proceeds totalling at
least EUR 15 million in the Offering and the UK Offering (taking into account
the binding Subscription Commitments and Subscription Guarantee Undertakings
received by the Company).

 

In addition, certain investors (the "Subscription Guarantors") have entered
into Subscription Guarantee Undertakings ("Subscription Guarantee
Undertakings") with the Company, according to which the Subscription
Guarantors have undertaken, subject to certain conditions, to subscribe for
any new shares of the Company that may not be subscribed for in the Offering
for a maximum amount of EUR 8.8 million. The Subscription Guarantees are
limited to cover any unsubscribed new shares of the Company only up to the
minimum amount of the Offering (EUR 15 million). The Subscription Guarantees
do not cover the UK Offering.

 

The Subscription Guarantee Undertakings are binding, irrevocable and subject
only to the fulfilment of the following conditions: (i) the subscription price
per new share of the Company in the Offering shall not exceed EUR 1.0, (ii)
the Board of Directors of the Company having no later than 30 June 2024
resolved to commence the Offering and (iii) the Company raises gross proceeds
totalling at least EUR 15 million in the Offering and the UK Offering (taking
into account the binding Subscription Commitments and Subscription Guarantee
Undertakings received by the Company).

 

Based on the binding Subscription Commitments and Subscription Guarantee
Undertakings received by the Company, the condition of EUR 15 million in gross
proceeds described above has been fulfilled.

 

Placing Agreement

 

On 3 June 2024, the Company and the Lead Managers have entered into a placing
agreement (the "Placing Agreement"), which sets out Carnegie's and Peel Hunt's
duties as the Lead Managers of the Offering.

The Placing Agreement contains customary terms and conditions, according to
which the Lead Managers have the right to terminate the Placing Agreement in
certain circumstances and subject to certain conditions. Such circumstances
include, but are not limited to, significant adverse changes in the business,
financial or other position or operating result of the Company, and certain
other changes in, among other things, national or global political or economic
conditions. Furthermore, Faron has given customary representations to the Lead
Managers in the Placing Agreement regarding, among other things, the business
and legal compliance of the Company, the Shares of the Company, and the
contents of the Prospectus. In addition, Faron has agreed to indemnify the
Lead Managers against certain liabilities in connection with the Offering.

 

Restriction on the Issue or Transfer of Shares (Lock-up)

 

The Company has undertaken not to issue new Shares or securities entitling to
Shares or rights attached to them without the written consent of the Lead
Managers, for a period that falls 90 days from the completion of the Offering,
with the exception of the Offer Shares, the Free Shares, the Shares issued to
the lenders of the Capital Loans in connection with the conversion of the
Capital Loans, the Shares issued under the warrants granted to IPF, and the
Shares to be issued in accordance with the terms of the Company's current
incentive schemes, as well as certain other customary exceptions. In the event
that the Offering will not be completed in the targeted amount of appr. EUR
30.7 million, the Lead Managers have agreed not to unreasonably withhold their
consent regarding issuance of any equity securities or any securities
exchangeable for or convertible into or exercisable for equity securities
proposed by the Company within the limits of the currently existing share
issuance authorisations granted to the Board.

 

Publication of the prospectus

 

The Company has prepared a Finnish language prospectus regarding the Offering
(the "Prospectus"), which the Finnish Financial Supervisory Authority has
approved on 3 June 2024. The Prospectus will be available in Finnish on the
Company's website at www.faron.com/osakeanti and on Nordnet Bank AB's website
at www.nordnet.fi/faron on 4 June 2024, at the latest. An unofficial
English-language translation of the Prospectus is expected to be available on
the Company's website at www.faron.com/publicoffer on or about 4 June 2024.

 

Important Dates for the Offering

 

·    The Subscription period for the Offering commences on 5 June 2024 at
10:00 a.m. (Finnish time)

·    The allocation preference of the Company's shareholders is determined
in the Offering on 6 June 2024 after 6:00 p.m. (Finnish time)

·    The Subscription period for the Public Offering ends on 18 June 2024
at 4:00 p.m. (Finnish time)

·    The Subscription period for the Institutional Offering ends on 19
June 2024 at 9:30 a.m. (Finnish time)

·    Announcement of the results of the Offering on 20 June 2024
(estimate)

·    The Offer Shares are registered in the Finnish Trade Register on 20
June 2024 (estimate)

·    The Offer Shares subscribed for in the Offering are recorded in the
book-entry accounts of investors on 24 June 2024 (estimate)

·    Trading in the Offer Shares commences on First North Growth Market
Finland and AIM on 24 June 2024 (estimate)

·    The Offer Shares subscribed for in the Institutional Offering are
ready for delivery against payment on 24 June 2024 (estimate)

 

Details of the UK Open Offer

 

The Company is proposing to raise up to approximately GBP 4.9 million before
expenses by the issue of up to 5,765,368 UK Open Offer Shares under the UK
Open Offer at the UK Issue Price of GBP 0.85 per share, payable in full on
acceptance. Any entitlements to UK Open Offer Shares not subscribed for by
Qualifying DI Holders will be available to Qualifying DI Holders under an
excess application facility (the "Excess Application Facility") that allows
Qualifying DI Holders to apply for UK Open Offer Shares in excess of their
entitlement to UK Open Offer Shares pro rata to their holding of Existing DIs
(as defined below) ("UK Open Offer Entitlement").

 

Qualifying DI Holders should note that the UK Open Offer is not a rights issue
and therefore the UK Open Offer Shares which Qualifying DI Holders do not
apply for will not be sold in the market for the benefit of Qualifying DI
Holders who do not apply for UK Open Offer Shares.

 

Qualifying DI Holders may apply for UK Open Offer Shares under the UK Open
Offer at the UK Issue Price pro rata to their holdings of existing DIs on the
record date of the UK Open Offer (the "Existing DIs") on the basis of:

 

3 UK Open Offer Shares for every 7 Existing DIs held

 

Entitlements of Qualifying DI Holders will be rounded down to the nearest
whole number of UK Open Offer Shares. Fractional entitlements which would
otherwise arise will not be issued to Qualifying DI Holders but will be
aggregated and made available under the Excess Application Facility. Not all
holders of DI will be Qualifying DI Holders. Shareholders who are located in,
or are citizens of, or have a registered office in, the United States,
Australia, Canada, Japan, New Zealand, the Republic of South Africa or any
jurisdiction the extension or availability of the UK Open Offer would breach
any applicable laws or regulations will not qualify to participate in the UK
Open Offer.

 

Subject to availability, the Excess Application Facility enables Qualifying DI
Holders to apply for UK Open

Offer Shares in addition to their UK Open Offer Entitlement ("Excess Shares")
up to the maximum number of UK Open Offer Shares available less their UK Open
Offer Entitlement.

 

Valid applications by Qualifying DI Holders will be satisfied in full up to
their UK Open Offer Entitlements. Applicants can apply for less or more than
their entitlements under the UK Open Offer, but the Company cannot guarantee
that any application for Excess Shares under the Excess Application Facility
will be satisfied, as this will depend, in part, on the extent to which other
Qualifying DI Holders apply for less than or more than their own UK Open Offer
Entitlements. The Company may satisfy valid applications for Excess Shares in
whole or in part but reserves the right not to satisfy any application above
any UK Open Offer Entitlement. The Board may scale back applications made in
excess of UK Open Offer Entitlements on such basis as it reasonably considers
to be appropriate.

 

Application has been made for the UK Open Offer Entitlements and the
entitlement to apply for UK Open

Offer Shares pursuant to the Excess Application Facility ("Excess CREST UK
Open Offer Entitlements") to be admitted to CREST. It is expected that such UK
Open Offer Entitlements and Excess CREST UK Open Offer Entitlements will be
credited to CREST on 5 June 2024. The UK Open Offer Entitlements and Excess
CREST UK Open Offer Entitlements will be enabled for settlement in CREST until
11.00 a.m. on 18 June 2024. Applications through the CREST system may only be
made by the Qualifying DI Holders originally entitled or by a person entitled
by virtue of bona fide market claims. The UK Open Offer Shares must be paid in
full on application. The latest time and date for receipt of CREST
applications by Qualifying DI Holders and payment in respect of the UK Open
Offer is 11.00 a.m. on 18 June 2024.

 

Qualifying DI Holders will receive a credit of UK Open Offer Entitlements and
Excess CREST UK Open Offer Entitlements to their CREST stock account.

 

The UK Open Offer Shares will be issued free of all liens, charges and
encumbrances and will, when issued and fully paid, rank pari passu in all
respects with the existing shares of the Company and the Offer Shares,
including the right to receive all dividends and other distributions declared,
made or paid after the date of their issue.

 

Application will be made to the London Stock Exchange for the admission of the
UK Open Offer Shares to trading on AIM and to Nasdaq Helsinki Ltd for the UK
Open Offer Shares to be admitted to trading on First North. It is expected
that admission of the UK Open Offer Shares to trading on AIM will occur, and
that dealings in the UK Open Offer Shares subscribed for pursuant to the UK
Open Offer on AIM will commence, at 8.00 a.m. on 24 June 2024, at which time
it is also expected that the UK Open Offer Shares will be enabled for
settlement in CREST.

 

Qualifying DI Holders should refer to the UK Open Offer Circular for more
information on, and full details of, the UK Open Offer and the terms and
conditions on which it is being made.

 

Important Dates for the UK Open Offer

 

 Record Date for the UK Open Offer                                            Close of business on 3 June 2024
 Announcement of the UK Open Offer                                             4 June 2024
 Ex-entitlement Date of the UK Open Offer                                     8:00 a.m. on 4 June 2024
 UK Open Offer Entitlements credited to CREST                                 8:00 a.m. on 5 June 2024

stock accounts of Qualifying DI Holders
 Latest time and date for acceptance of the                                   11:00 a.m. on 18 June 2024

UK Open Offer by Qualifying DI holders through CREST
 Announcement of the result of the UK Open Offer                              20 June 2024
 Admission of the UK Open Offer Shares to trading on First North and          8:00 a.m. on 24 June 2024
 commencement of dealings
 Admission of the UK Open Offer Shares to trading on AIM and commencement of  8:00 a.m. on 24 June 2024
 dealings
 Expected date for CREST accounts to be credited in respect of UK Open Offer  24 June 2024
 Shares in uncertificated form

Notes

(1)   Each of the times and dates set out in the above timetable and
mentioned in this document is subject to change by the Company, in which event
details of the new times and dates will be notified to the London Stock
Exchange and the Company will make an appropriate announcement via a
Regulatory Information Service.

(2)   References to times in this document are to London time unless
otherwise stated.

 

Publication of the UK Open Offer Circular

 

The terms and conditions of the UK Open Offer will be set out in the UK Open
Offer Circular to be sent to Qualifying DI Holders in the United Kingdom and
elsewhere. It is expected that the UK Open Offer Circular will be dispatched
on or around 4 June 2024, and will also be available at this time on the
Company's website at www.faron.com/investors.

 

Webinars

 

Faron will be hosting two virtual webinars for investors and analysts on 6
June 2024. The webinar beginning at 5:30 p.m. (EEST) / 2:30 p.m. (GMT) / 10:30
a.m. (EDT) will be held in Finnish and the webinar beginning at 7:00 p.m.
(EEST) / 4:00 p.m. (GMT) / 12 noon (EDT) will be held in English. Dr. Juho
Jalkanen, CEO of Faron, and Yrjö Wichmann, Interim CFO of Faron, will be
presenting at the webinars.

 

Questions may be presented during the webinar. To register for the webinar,
please visit https://faron.videosync.fi/yritysesittely_2024. Contact the IR
team for more information at investor.relations@faron.com.

 

Carnegie Investment Bank AB, Finland Branch and Peel Hunt LLP are acting as
the Lead Managers of the Offering and as the subscription places in the
Institutional Offering. Carnegie is not participating in arranging the UK Open
Offer or the REX Retail Offer and Peel Hunt is not participating in arranging
the UK Open Offer. In addition, Nordnet Bank AB acts as the subscription place
in the Public Offering and as a subscription place in the Institutional
Offering for its own customers.

 

Related party and PDMR filing

 

Christine Roth, a director of the Company, has committed to subscribe for
46,075 Offer Shares. Her interests in the issued shares and votes of the
Company are set out below:

 

                 Before the Offering                                                                                                      Following the Offering
 Director        Number of ordinary shares held  % of issued shares and voting rights  Number of Offer Shares committed to subscribe for  Number of ordinary shares held  % of issued shares and votes
 Christine Roth  0                               0                                     46,075                                             46,075                          0.04

 

The participation of Christine Roth ("Director Participation") in the Offering
constitutes a related party transaction for the purposes of the AIM Rules, the
First North Rulebook and the Finnish Limited Liability Companies Act. The
independent directors for the purpose of the Director Participation, being all
other members of the Board, having consulted with Cairn Financial Advisers
LLP, the Company's nominated adviser for the purposes of the AIM Rules,
consider the terms of the Director Participation in the Offering to be fair
and reasonable insofar as shareholders are concerned.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Christine Roth
 2   Reason for notification

 a.  Position/Status                                              Member of the Board
 b.  Initial notification/                                        Initial Notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Faron Pharmaceuticals Oy
 b.  LEI                                                          7437009H31TO1DC0EB42
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Share

Identification Code
ISIN: FI4000153309
 b.  Nature of the transaction                                    Subscription of shares
 c.  Price(s) and volume(s)                                                    Average
                                                                              Price(s)    Volume(s)
     1.00                                                                     46,075

 d.  Aggregated information

     - Aggregated Volume                                          46,075

     - Price                                                      1.00

 e.  Date of the transaction                                      20 June 2024
 f.  Place of the transaction                                     Outside of trading venue

 

 

The terms of the Offering are available
at http://www.faron.com/investors/publicoffer
(http://www.faron.com/investors/publicoffer)

For the purposes of MAR and UK MAR, the person responsible for arranging for
the release of this

announcement on behalf of Faron is Juho Jalkanen, Chief Executive Officer.

 

Faron Pharmaceuticals Ltd

 

 

For more information please contact:

ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com (mailto:faron@consilium-comms.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

About BEXMAB

 

The BEXMAB study is an open-label Phase I/II clinical trial investigating
bexmarilimab in combination with standard of care (SoC) in the aggressive
hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS). The primary objective is to determine the safety and
tolerability of bexmarilimab in combination with SoC (azacitidine) treatment.
Directly targeting Clever-1 could limit the replication capacity of cancer
cells, increase antigen presentation, ignite an immune response, and allow
current treatments to be more effective. Clever-1 is highly expressed in both
AML and MDS and associated with therapy resistance, limited T cell activation
and poor outcomes.

 

About bexmarilimab

 

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune system.
Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on
macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on macrophages,
bexmarilimab alters the tumor microenvironment, reprogramming macrophages from
an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating
interferon production and priming the immune system to attack tumors and
sensitizing cancer cells to standard of care.

 

About Faron Pharmaceuticals Ltd

 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments. Further information is available at www.faron.com
(http://www.faron.com) .

 

Important notice

 

This announcement is not an offer of securities for sale into the United
States. The Offer Shares have not been and will not be registered under the
United States Securities Act of 1933, as amended (the "Securities Act"), or
under the securities laws of any state or other jurisdiction of the United
States, and may not be offered, sold or transferred, directly or indirectly,
in or into or from the United States except pursuant to an exemption from, or
in a transaction not subject to, the registration requirements of the
Securities Act and in compliance with any applicable securities laws of any
state or other jurisdiction of the United States. There is no intention to
register the Offer Shares in the United States or to make a public offering in
the United States. Any sale of the Offer Shares in the United States will be
made solely to a limited number of "qualified institutional buyers" or
accredited investors, each as defined in Rule 144A in reliance on an exemption
from the registration requirements of the Securities Act.

 

The distribution of this release may be restricted by law and persons into
whose possession any document or other information referred to herein comes
should inform themselves about and observe any such relevant legal
restrictions. The information contained herein is not for publication or
distribution, directly or indirectly, in or into the United States, Australia,
Canada, Japan, New Zealand or the Republic of South Africa. Any failure to
comply with these restrictions may constitute a violation of the securities
laws of any such aforementioned jurisdiction. This release is not directed to,
and is not intended for distribution to or use by, any person or entity that
is a citizen, resident or located in any locality, state, country or other
jurisdiction where such distribution, publication, availability or use would
violate law or regulation or which would require any registration or licensing
within such jurisdiction.

 

In any EEA Member State, other than Finland, this release is only addressed to
and is only directed at "qualified investors" in that Member State within the
meaning of Article 2(e) of Regulation (EU) 2017/1129 (the "Prospectus
Regulation").

 

In the United Kingdom, this release is only being distributed to and is only
directed at "qualified investors" within the meaning of Article 2(e) of the
Prospectus Regulation as it forms part of domestic law in the United Kingdom
by virtue of the European Union (Withdrawal) Act 2018 (the "UK Prospectus
Regulation") who are (i) investment professionals falling within Article 19(5)
of the Financial Services and Markets Act 2000 (Financial Promotion) Order
2005 (the "Order") or (ii) high net worth companies, and other persons to whom
it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the
Order (all such persons together being referred to as "UK Relevant Persons").
Any securities mentioned herein are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such securities
will be engaged in only with, in the United Kingdom, UK Relevant Persons. Any
person who is not a UK Relevant Person should not act or rely on this release
or any of its contents. The UK Open Offer is only available to persons in the
United Kingdom falling within Article 43 of the Order.

 

This release does not constitute a prospectus as defined in either the
Prospectus Regulation or the UK Prospectus Regulation and, as such, it does
not constitute or form part of, and should not be construed as, an offer to
sell, or a solicitation or invitation of any offer to buy, acquire or
subscribe for, any securities or an inducement to enter into investment
activity in relation to any securities.

 

No part of this release, nor the fact of its distribution, should form the
basis of, or be relied on in connection with, any contract or commitment or
investment decision whatsoever. The information contained in this release has
not been independently verified. No representation, warranty or undertaking,
expressed or implied, is made as to, and no reliance should be placed on, the
fairness, accuracy, completeness or correctness of the information or the
opinions contained herein. The Company or any of its respective affiliates,
advisors or representatives or any other person, shall have no liability
whatsoever (in negligence or otherwise) for any loss, however arising from any
use of this release or its contents or otherwise arising in connection with
this release. Each person must rely on their own examination and analysis of
the Company, its subsidiaries, its securities and the transactions, including
the merits and risks involved.

 

The Lead Managers are acting exclusively for the Company and no one else in
connection with the Offering. They will not regard any other person as their
respective client in relation to the Offering. The Lead Managers will not be
responsible to anyone other than the Company for providing the duties afforded
to their respective clients, nor for giving advice in relation to the Offering
or any transaction or arrangement referred to herein.

 

Caution regarding forward-looking statements

 

Certain statements in this announcement are, or may be deemed to be,
forward-looking statements. Forward-looking statements are identified by their
use of terms and phrases such as ''believe'', ''could'', "should", "expect",
''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'',
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Company's current expectations and
assumptions regarding the completion and use of proceeds from the Offering,
the Company's future growth, results of operations, performance, future
capital and other expenditures (including the amount, nature and sources of
funding thereof), competitive advantages, business prospects and
opportunities. Such forward-looking statements reflect the Company's current
beliefs and assumptions and are based on information currently available to
the Company.

 

A number of factors could cause actual results to differ materially from the
results and expectations dis-cussed in the forward-looking statements, many of
which are beyond the control of the Company. In addition, other factors which
could cause actual results to differ materially include the ability of the
Company to successfully licence its programmes, risks associated with
vulnerability to general economic and business conditions, competition,
environmental and other regulatory changes, actions by governmental
authorities, the availability of capital markets or other sources of funding,
reliance on key personnel, uninsured and underinsured losses and other
factors. Although any forward-looking statements contained in this
announcement are based upon what the Company believes to be reasonable
assumptions, the Company cannot assure investors that actual results will be
consistent with such forward-looking statements. Accordingly, readers are
cautioned not to place undue reliance on forward-looking statements. Subject
to any continuing obligations under applicable law or any relevant AIM Rule
requirements, in providing this information the Company does not undertake any
obligation to publicly update or revise any of the forward-looking statements
or to advise of any change in events, conditions or circumstances on which any
such statement is based.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEASKLELDLEEA